BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Trastuzumab Deruxtecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Trastuzumab Deruxtecan\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06048718-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06048718)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: T-DXd Therapy for HER2-low Breast Cancer Patients With Bra
 in Metastases\nEstimated primary completion: November 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06048718
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06250777-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06250777)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer P
 atients With Asymptomatic Brain Metastases\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastu
 zumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06250777
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06331169-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT06331169)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Anlotinib With Trastuzumab Deruxtecan for Previously Treat
 ed HER2-Low Advanced Breast Cancer\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab
 -deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06331169
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585958-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT04585958)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1.\nStudy: Testing the Combinati
 on of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in P
 atients With Platinum Resistant Ovarian Cancer\nEstimated primary completi
 on: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04585958
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06486883-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06486883)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First
 -line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer 
 Patients Classified as Non-luminal Subtype\nEstimated primary completion: 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuz
 umab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06486883
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797622-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06797622)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd T
 reatment for Brain Metastasis of HER2 Positive Breast Cancer\nEstimated pr
 imary completion: 15 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06797622
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134153-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT07134153)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Exp
 ressing Breast Cancer With Leptomeningeal/Brain Metastases\nEstimated prim
 ary completion: 30 January 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07134153
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06271837-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06271837)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of T-DXd as Monotherapy or in Combination With Ant
 i-cancer Agents in Patients With Selected HER2-expressing Tumors\nEstimate
 d primary completion: 10 February 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06271837
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06253650-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06253650)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Adjuvant TRastuzumab 
 Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of m
 iNImal Residual Disease\nEstimated primary completion: 1 March 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0625365
 0
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04482309-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT04482309)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: A Phase 2 Study of T-
 DXd in Patients With Selected HER2 Expressing Tumors\nEstimated primary co
 mpletion: 23 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04482309
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04704661-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT04704661)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1\, Breast Cancer.\nStudy: Testi
 ng the Combination of Two Anti-cancer Drugs\, DS-8201a and AZD6738\, for T
 he Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene\
 , The DASH Trial\nEstimated primary completion: 31 March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04704661
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06409390)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Sequential Therapies Modeled on Evolutionary Dynamics for 
 Breast Cancer\nEstimated primary completion: April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172127-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06172127)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresect
 able Locally Recurrent or Metastatic Breast Cancer\nEstimated primary comp
 letion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 rastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06172127
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05376878-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Trastuzumab Deruxtecan: Phase 4 readout est. (NCT05376878)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 4\, Breast Cancer.\nStudy: An In
 vestigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients Wit
 h HER2+ Breast Cancer With Brain Metastasis\nEstimated primary completion:
  27 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trast
 uzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05376878
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05900206-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT05900206)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for 
 HER2-positive Breast Cancer\nEstimated primary completion: 30 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 900206
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845450-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT05845450)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Pre-operative Targete
 d Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN
 )\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05845450
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04784715-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT04784715)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: Trast
 uzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane\, Trast
 uzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-B
 reast09)\nEstimated primary completion: 3 May 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04784715
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04379596-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT04379596)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Ph1b/2 Study of the S
 afety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastr
 ic Cancer (DESTINY-Gastric03)\nEstimated primary completion: 4 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT043
 79596
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Study of AZD5305 as Monotherapy and in Combination With Anti-can
 cer Agents in Patients With Advanced Solid Malignancies\nEstimated primary
  completion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04644068
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05274048-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT05274048)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1.\nStudy: Neratinib and Fam-Tra
 stuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients\nEstimat
 ed primary completion: June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05274048
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05614739-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT05614739)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1.\nStudy: FORAGER-1: A Study of
  Vepugratinib (LY3866288\; LOXO-435) in Participants With Cancer With a Ch
 ange in a Gene Called FGFR3\nEstimated primary completion: June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT056147
 39
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832202-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06832202)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase II Study of HLX22 in Combination With Trastuzumab 
 Deruxtecan in HER2-low\, Hormone Receptor Positive Locally Advanced or Met
 astatic Breast Cancer Patients\nEstimated primary completion: 1 June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6832202
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368543-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07368543)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic 
 Breast Cancer\nEstimated primary completion: 1 June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07368543
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012031-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT07012031)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Sotorasib in Combination With Trastuzumab Deruxtecan for the Tre
 atment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With 
 a KRAS G12C Mutation\nEstimated primary completion: 14 June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07012031
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04686305-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT04686305)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1\, Non-Small Cell Lung Cancer.\
 nStudy: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents Wit
 h and Without Chemotherapy in Advanced or Metastatic HER2+\, Non-squamous 
 NSCLC\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04686305
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364410-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270708
DTEND;VALUE=DATE:20270709
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT06364410)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1.\nStudy: Testing the Combinati
 on of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosert
 ib (ZN-c3) in Patients With Stomach or Other Solid Tumors\nEstimated prima
 ry completion: 8 July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06364410
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086768-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270807
DTEND;VALUE=DATE:20270808
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT07086768)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1.\nStudy: Dose-Escalation and D
 ose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patient
 s With Advanced or Metastatic Solid Tumors\nEstimated primary completion: 
 7 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastu
 zumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07086768
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05593094-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT05593094)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, HER2-Positive Breast Cance
 r.\nStudy: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in
  Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positiv
 e Advanced Solid Tumors\nEstimated primary completion: 31 August 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05593
 094
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150208-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07150208)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: T-DXd With or Without Bevacizumab for HER2-low Breast Canc
 er With Brain Metastasis\nEstimated primary completion: September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0715
 0208
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825753-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07825753)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Protein-Matched ADC or PDC Umbrella Trial in Advanced Panc
 reatic and Breast Cancer\nEstimated primary completion: 1 September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 825753
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06058988-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270922
DTEND;VALUE=DATE:20270923
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06058988)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Trastuzumab Deruxteca
 n (T-DXd) for People With Brain Cancer\nEstimated primary completion: 22 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastu
 zumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06058988
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393425-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07393425)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: Neoad
 juvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Can
 cer\nEstimated primary completion: 30 September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07393425
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06610825-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06610825)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Castrate Resistant Pr
 ostate Cancer Enhertu Therapy\nEstimated primary completion: October 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6610825
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05982678-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT05982678)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Basket Study for Oligo-metastatic Breast Cancer\nEstimated
  primary completion: 1 October 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05982678
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05950945-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT05950945)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormon
 e Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 M
 etastatic Breast Cancer\nEstimated primary completion: 1 October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05950
 945
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407465-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07407465)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Upfront Trastuzumab-D
 eruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positi
 ve Metastatic Colorectal Cancer.\nEstimated primary completion: 20 October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-de
 ruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07407465
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203378-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07203378)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Nurturing Exercise Routine for Greater Improvement in Zest
  and Energy on Enhertu\nEstimated primary completion: November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0720337
 8
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07069712-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271109
DTEND;VALUE=DATE:20271110
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07069712)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: A Study of Novel Agen
 ts or Combinations as Perioperative Treatment in Participants With Locally
  Advanced Resectable Gastroesophageal Adenocarcinoma\nEstimated primary co
 mpletion: 9 November 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07069712
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318389-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT07318389)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1.\nStudy: ASCEND-CRC: Profiling
  and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colore
 ctal Cancer\nEstimated primary completion: 14 November 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07318389
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06085755-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT06085755)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2.\nStudy: Trastuzumab Deruxte
 can(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer\nE
 stimated primary completion: 1 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06085755
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05795101-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT05795101)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: TRUDI: TDXD+Durva in HER2+/Low IBC\nEstimated primary completion:
  1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tra
 stuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05795101
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647016-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07647016)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trastuzumab Deruxtecan Plus ivonescImab for Hormone Recept
 or-positive HER2 Negative Advanced Breast Cancer Study\nEstimated primary 
 completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07647016
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731803-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT06731803)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2.\nStudy: Platform Trial Eval
 uating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combinat
 ion Therapies for HER2+\, Resectable Esophagogastric Adenocarcinoma\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06731803
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: TAPUR: Testing the Us
 e of Food and Drug Administration (FDA) Approved Drugs That Target a Speci
 fic Abnormality in a Tumor Gene in People With Advanced Stage Cancer\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662473-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07662473)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or M
 etastatic NSCLC With HER2 Over Expression\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tras
 tuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07662473
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04616560-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT04616560)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Trastuzumab Deruxteca
 n (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma\, W
 ilms Tumor\, and Desmoplastic Small Round Cell Tumor\nEstimated primary co
 mpletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04616560
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07162259-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab Deruxtecan: Phase 4 readout est. (NCT07162259)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 4\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Cohort Study on Sequential ADC Therapy in HR-positive/HER2
 -negative Advanced Breast Cancer\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-d
 eruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07162259
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771622-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT06771622)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2.\nStudy: Safety and Efficacy
  of HCB101 in Combination With Multiple Agents in Patients With Advanced S
 olid Tumors\nEstimated primary completion: 1 January 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06771622
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06733233-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06733233)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: A Stu
 dy Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combina
 tion with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 
 Low-expressing Chinese Patients with Early-stage Breast Cancer\nEstimated 
 primary completion: 1 January 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06733233
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533826-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06533826)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: TReatment of ADC-Refractory Breast CancEr With Dato-DXd or
  T-DXd: TRADE DXd\nEstimated primary completion: 1 January 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06533826
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07137416-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT07137416)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Testing the Safety of the Combination of Anti-Cancer Drugs
  CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epiderm
 al Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
 \nEstimated primary completion: 10 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07137416
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05417594-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280207
DTEND;VALUE=DATE:20280208
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT05417594)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2.\nStudy: Study of AZD9574 as
  Monotherapy and in Combination With Anti-cancer Agents in Participants Wi
 th Advanced Solid Malignancies\nEstimated primary completion: 7 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deru
 xtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05417594
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06174987-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06174987)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: A Study to Provide Co
 ntinued Access to and Assess Long-Term Safety of the Study Drug(s)\nEstima
 ted primary completion: 17 February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06174987
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05034887-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT05034887)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Phase 2 Study of Tras
 tuzumab Deruxtecan in the Neoadjuvant Treatment\, or Trastuzumab Deruxteca
 n Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Post
 operative Adjuvant Treatment for Patients With HER2 Positive Gastric and G
 astroesophageal Junction Adenocarcinoma\nEstimated primary completion: 31 
 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzum
 ab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05034887
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311214-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06311214)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Personalized Antibody
 -Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment
  of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treat
 ment Trial)\nEstimated primary completion: 31 March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06311214
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905313-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07905313)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: Study
  of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery i
 n Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis
  of Brain Metastases (HERBRAIN)\nEstimated primary completion: 15 May 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxte
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07905313
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497386-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07497386)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Trial of Trastuzumab Rezetecan in Unresectable Locally R
 ecurrent/Metastatic Breast Cancer\nEstimated primary completion: June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxte
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07497386
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198724-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT07198724)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trast
 uzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistan
 t HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer\nEstimated primar
 y completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07198724
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04986579-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT04986579)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Scalp Cooling in MBC\nEstimated primary completion: 1 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-de
 ruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04986579
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731478-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06731478)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: Study of TDXd\, Chemo
 therapy\, Pembrolizumab\, and Trastuzumab in First-Line Metastatic HER2-Po
 sitive Gastric or Gastroesophageal Junction Cancer\nEstimated primary comp
 letion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06731478
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06467357-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280612
DTEND;VALUE=DATE:20280613
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06467357)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: Phase 3 Study of T-DX
 d and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract C
 ancer\nEstimated primary completion: 12 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06467357
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06145308)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Precision Treatment o
 f Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
 \nEstimated primary completion: 10 July 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05372614-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280717
DTEND;VALUE=DATE:20280718
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT05372614)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1.\nStudy: Testing the Safety an
 d Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratin
 ib for Cancers With Changes in the HER2 Gene\nEstimated primary completion
 : 17 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trast
 uzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05372614
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05408845-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT05408845)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Testing the Use of Ad
 o-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With
  Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent\, Met
 astatic\, or Unresectable HER2-Expressing Salivary Gland Cancers\nEstimate
 d primary completion: 31 July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05408845
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07157956-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280812
DTEND;VALUE=DATE:20280813
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT07157956)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2.\nStudy: CVL006 Combination 
 Therapy in Advanced Solid Tumors\nEstimated primary completion: 12 August 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-der
 uxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07157956
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06525298-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT06525298)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2.\nStudy: EIS-12656 as Single
  Agent and in Combination in Patients With Specified Solid Tumors\nEstimat
 ed primary completion: September 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06525298
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619521-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280908
DTEND;VALUE=DATE:20280909
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT07619521)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2.\nStudy: Testing the Combina
 tion of Anti-Cancer Drugs\, Selumetinib and DS-8201a (Trastuzumab Deruxtec
 an)\, for Advanced Pancreatic Ductal Adenocarcinoma\nEstimated primary com
 pletion: 8 September 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07619521
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630130-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06630130)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Perioperative Therapi
 es in Locally Advanced Unresectable Gastric Cancer\nEstimated primary comp
 letion: 30 October 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06630130
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836257-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07836257)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: A Pha
 se II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Posit
 ive Advanced Breast Cancer After Progression on T-DXd\nEstimated primary c
 ompletion: 30 October 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07836257
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06244485-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT06244485)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1.\nStudy: A Study of Valemetost
 at Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors\nEs
 timated primary completion: 1 November 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06244485
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126561-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07126561)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Trastuzumab Deruxteca
 n to Treat HER2 + Newly Diagnosed Metastatic GI Cancers\nEstimated primary
  completion: 1 November 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07126561
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819007-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06819007)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: Study of Trastuzumab 
 Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line 
 Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)\nEstimat
 ed primary completion: 1 November 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06819007
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07785856-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT07785856)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, Breast Cancer.\nStudy: Stu
 dy of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor 
 in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Brea
 st Cancer\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07785856
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07130344-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab Deruxtecan: Phase na readout est. (NCT07130344)
DESCRIPTION:Trastuzumab Deruxtecan\, phase na\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: PERCIST Evaluation of Trastuzumab Deruxtecan in the Treat
 ment of HER2 Low Breast Cancer\nEstimated primary completion: December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxt
 ecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07130344
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015697-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT07015697)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1.\nStudy: A Study of Subcutaneo
 us Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors\nEs
 timated primary completion: 31 December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07015697
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06750484-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06750484)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trial of Trastuzumab Deruxtecan in Previously Treated HER2
 \nEstimated primary completion: 31 December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06750484
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324357-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT06324357)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, Breast Cancer.\nStudy: Bea
 mion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and
  in Combination With Other Treatments to Test Whether it Helps People With
  Different Types of HER2+ Cancer That Has Spread\nEstimated primary comple
 tion: 8 January 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06324357
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989112-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20290119
DTEND;VALUE=DATE:20290120
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06989112)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: DESTINY-Endometrial01
 : A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembro
 lizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+)\, Mismatch 
 Repair Proficient (pMMR) Endometrial Cancer\nEstimated primary completion:
  19 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tra
 stuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06989112
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454668-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT07454668)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1\, HER2-Positive Breast Cancer.
 \nStudy: Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+
  Breast Cancer Brain Metastases\nEstimated primary completion: February 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-derux
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07454668
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840886-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT06840886)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of PHST001 in Advanced Solid Tumors\nEstimated pri
 mary completion: April 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06840886
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764875-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06764875)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: A Phase Ⅲ Study of 
 Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxte
 can as the First-line Treatment for HER2-positive Gastric Cancer\nEstimate
 d primary completion: 27 April 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06764875
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05765851-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT05765851)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1.\nStudy: A Study of DS-1103a C
 ombination Therapy in Participants With Advanced Solid Tumors\nEstimated p
 rimary completion: 31 May 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05765851
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691489-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07691489)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: A Study of Trastuzuma
 b Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer\nEstim
 ated primary completion: June 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07691489
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782086-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Trastuzumab Deruxtecan: Phase na readout est. (NCT07782086)
DESCRIPTION:Trastuzumab Deruxtecan\, phase na\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic 
 Breast Cancer\nEstimated primary completion: July 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07782086
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371585-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07371585)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: Trast
 uzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer Wit
 h Proactive Toxicity Management\nEstimated primary completion: 1 August 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-derux
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07371585
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151586-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07151586)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: Testi
 ng Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) 
 Combinations Prescribed in an Alterning Pattern to Patients With Metastati
 c or Locally Advanced Triple-negative Breast Cancer\nEstimated primary com
 pletion: October 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07151586
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07195344-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Trastuzumab Deruxtecan: Phase 4 readout est. (NCT07195344)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 4\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study Aiming to Compare the Plasma Exposure of the Payload
  (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastati
 c Breast Cancer According to Their BMI.\nEstimated primary completion: Oct
 ober 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07195344
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07022483-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20300226
DTEND;VALUE=DATE:20300227
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT07022483)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: A Study of Trastuzuma
 b Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC
  3+/2+) Endometrial Cancer in Adjuvant Setting\nEstimated primary completi
 on: 26 February 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07022483
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459673-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07459673)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-
 HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission\nEstimate
 d primary completion: 4 March 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07459673
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439693-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06439693)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HER2-Positive Breast Cancer.
 \nStudy: The SAPPHO Study: Sequential Therapy With Curative Intent in de N
 ovo HER2+ Metastatic Breast Cancer\nEstimated primary completion: 30 March
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-de
 ruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06439693
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06899126-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20300424
DTEND;VALUE=DATE:20300425
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06899126)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Trastuzumab Deruxtecan\, Pembrolizumab\, and Platinum-bas
 ed Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Canc
 er\nEstimated primary completion: 24 April 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06899126
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05704829-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT05704829)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: NeoAd
 juvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab
 +Pertuzumab in HER2+ Early Breast Cancer\nEstimated primary completion: Ju
 ne 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-
 deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05704829
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683754-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20300704
DTEND;VALUE=DATE:20300705
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT07683754)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: T-DXd Based Therapy Followed by Endocrine Therapy Plus Dua
 l HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retr
 eatment With T-DXd\nEstimated primary completion: 4 July 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07683754
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple T
 reatment Combinations in Patients With Metastatic or Locally Advanced Brea
 st Cancer\nEstimated primary completion: 30 September 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619365-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07619365)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultr
 alow Advanced or Metastatic Breast Cancer\nEstimated primary completion: 3
 0 November 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tras
 tuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07619365
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828054-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20301220
DTEND;VALUE=DATE:20301221
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT07828054)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Premedication With Dexamethasone for Preventing Interstiti
 al Lung Disease in Patients With Breast Cancer Treated With Trastuzumab De
 ruxtecan\nEstimated primary completion: 20 December 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07828054
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05868226-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT05868226)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: PRE-ISPY Phase I/II Oncology Platform Program\nEstimated
  primary completion: 30 December 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05868226
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633979-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT05633979)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combina
 tion With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null 
 Metastatic Breast Cancer\nEstimated primary completion: 31 December 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 633979
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578116-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT07578116)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HER2-Positive Breast Cancer.
 \nStudy: Adding Surgery and Radiation to the Usual Treatment for HER2-Posi
 tive Breast Cancer That Had Already Spread at Diagnosis\nEstimated primary
  completion: 31 May 2032. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07578116
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07936422-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20330228
DTEND;VALUE=DATE:20330301
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07936422)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Trial Evaluating the Anti-tumor Activity of Antibody-based Thera
 pies in Metastatic Cancer Patients\nEstimated primary completion: February
  2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-de
 ruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07936422
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07553390-2164@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20360330
DTEND;VALUE=DATE:20360331
SUMMARY:Trastuzumab Deruxtecan: Phase 1 readout est. (NCT07553390)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Tr
 eatment-Refractory Breast Cancers\nEstimated primary completion: 30 March 
 2036. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-der
 uxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07553390
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
